News

InSphero announced a new collaborative partnership with Hesperos, uniting two leading innovators in the field of advanced in vitro and microphysiological (MPS) systems.

InSphero announced a new collaborative partnership with Hesperos, uniting two leading innovators in the field of advanced in vitro and microphysiological (MPS) systems.

InSphero has entered into a distribution agreement with Tessara Therapeutics, an Australian biotech company known for its advanced neuronal microtissue technology. This agreement further strengthens our portfolio of physiologically relevant 3D models and enables us to offer best-in-class neuronal assays to our global customer base.

InSphero is proud to announce that Chief Scientific Officer, Dr. Madhu Nag, has been appointed as a member of the Society for Laboratory Automation and Screening (SLAS) Board of Directors, serving a three-year term starting January 1, 2025. Dr. Nag will also take on the role of Board Secretary.

InSphero, the global leader in scalable and reliable 3D in vitro cell culture solutions for drug discovery, takes a leading role in the recently awarded Chips JU European UNLOOC Project to advance its technology platform and address diversity in drug efficacy and safety testing.

InSphero, the global leader in 3D cell culture technology, and scientists from the U.S. FDA's NCTR have published the largest-ever benchmarking study on liver toxicity using 3D InSight™ Human Liver Microtissues.

InSphero, the global leader in 3D cell culture technology, and scientists from the U.S. FDA's NCTR have published the largest-ever benchmarking study on liver toxicity using 3D InSight™ Human Liver Microtissues.

InSphero, a leading innovator in 3D Cell Culture and Organ-on-Chip technology, has announced a new collaboration with Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, and the Université Libre de Bruxelles (ULB) Center for Diabetes Research.

InSphero AG is pleased to announce its exclusive commercialization of TrueCardium® Cardiac Organoid Platform in partnership with Genome Biologics.

In a notable collaboration that underscores the power of innovation in drug discovery, SanaGen and InSphero, alongside the renowned Sanquin research institute, have been awarded a 1.3 million euro grant for the ambitious project NOCAAVAAT.

InSphero's Liver Disease team has published a groundbreaking peer-reviewed paper in Nature's Scientific Reports, challenging the limitations of MASH Drug Discovery.

InSphero, the global leader in 3D in vitro technology for drug safety and efficacy testing, is proud to announce the appointment of Paul Clémençon, MBA as the new Chief Business Officer (CBO), further strengthening its Executive team.